News and Events

Events

2017 Evercore ISI Biopharma Catalyst/Deep Dive Conference
Nov 30, 2017 8:20 AM ET
29th Annual Piper Jaffray Healthcare Conference
Nov 28, 2017 10:30 AM ET
Adamas Third Quarter 2017 Financial Results
Nov 2, 2017 4:30 PM ET

Our Approach

Sources of Time-Dependent Biology

We are using time to fundamentally change the treatment experience of people with chronic neurologic diseases. We search for time-dependent patterns in diseases to reshape the timing of medicines and drive significant clinical outcomes for people in need.

Our exploration revolves around the knowledge that biological pathways and responses involve elements of time. We first map complex disease and drug activity patterns. From there, we design medicines with profiles that match the pattern of disease activity to drug levels to achieve therapeutic drug concentrations when needed most. We strive to create medicines with more significant and durable clinical effect without compromising tolerability. Our medicines are designed and developed to be timed to benefit patients.

Disease patterns
Due to the underlying biology, the occurrence and severity of disease symptoms may change throughout the day

Initial rate-of-rise in drug concentration
The speed at which drug concentration increases in the body may drive tolerability and efficacy responses

Timing of drug response
Matching the timing of drug levels to disease patterns may maximize treatment benefit

Pathway sequence
Drugs acting sequentially along a pathway may produce an outcome that is greater than the sum of the individual effects (synergy)

Our Leaders

Executive Management

Gregory T. Went, PhD
Founder, Chairman and Chief Executive Officer

Richard A. King
Chief Operating Officer

Alfred G. Merriweather
Chief Financial Officer

Rajiv Patni, MD
Chief Medical Officer

Christopher B. Prentiss
Chief Accounting Officer

Jennifer J. Rhodes
Chief Business Officer, General Counsel, Chief
Compliance Officer, and Corporate Secretary

 

Board of Directors

Gregory T. Went, PhD
Founder, Chairman and Chief Executive Officer

Michael F. Bigham

Martha J. Demski

Mardi C. Dier

William Ericson, JD

Ivan Lieberburg, MD, PhD

John MacPhee, MPH

David L. Mahoney

Gregory T. Went, PhD

Founder, Chairman and Chief Executive Officer

Dr. Went is the founder, chairman, and CEO of Adamas Pharmaceuticals and has guided the company’s growth since its inception in 2000. Dr. Went developed the original scientific approach, based upon the understanding and modeling of time-dependent biological phenomena. He has steered Adamas through the licensing of assets related to Namenda XR and Namzaric to Forest Laboratories (now Allergan), the company’s IPO, and steered the company through the development of Gocovri and the commercial launch of a new medicine for patients with Parkinson’s disease. Prior to Adamas, Dr. Went co-founded CuraGen Corporation in 1992, one of the first genomics companies, where he served as executive vice president and director. He has served on the board of directors of Angelica, Parallele Biosciences, and Tethys Biosciences.

Dr. Went has published in the fields of catalysis, spectroscopy, DNA sequencing, gene expression profiling, neuroscience, influenza, and neurology. An inventor with more than 70 issued and pending patents, he received his PhD in chemical engineering from the University of California, Berkeley, his BS in chemical engineering from Carnegie Mellon University, and completed additional post-doctoral work at Cornell University.

Alfred G. Merriweather

Chief Financial Officer

Mr. Merriweather joined the company in June 2017. Before
coming to Adamas, he was chief financial officer at RainDance
Technologies, Inc. Prior to RainDance, he served as chief financial
officer of Verinata Health, Inc. and as chief financial officer of
Celera Corporation. Mr. Merriweather previously spent more than 25
years in senior financial positions at several private and public
life science companies, including Monogram Biosciences, Inc. and
Laserscope. Mr. Merriweather received a bachelor’s degree from the
University of Cambridge in the United Kingdom.

Richard A. King

Chief Operating Officer

Mr. King joined the company in April 2017. Before coming to Adamas, he was COO at The Scripps Research Institute. He previously served as president and CEO of AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company developing new pain medications. Prior to AcelRx, Mr. King was president and COO of the biotechnology company Tercica, Inc. (later acquired by the Ipsen Group), where he was instrumental in the commercial launch of Dysport, Somatulin Autogel and Increlex. He also previously served as executive vice president of commercial operations at Kos Pharmaceuticals, Inc., where he oversaw the growth of Niaspan® (niacin extended-release) and the launch of Advicor® (niacin extended-release/lovastatin). Additionally, Mr. King was senior vice president of commercial operations at Solvay and vice president of Commercial Operations at Unimed, where he launched AndroGel®(testosterone gel). He received a BSc in chemical engineering from the University of Surrey in the UK and an MBA from the Manchester Business School in the UK.

Rajiv Patni, MD

Chief Medical Officer

Dr. Patni joined Adamas as chief medical officer in June 2015. Dr. Patni brings more than 15 years of global drug development experience across multiple therapeutic areas as well as extensive knowledge of the drug approval process. Prior to joining Adamas, Dr. Patni served as chief development officer at Ocera Therapeutics. Earlier in his career, he served as SVP (chief medical officer) at Actelion US Pharmaceuticals, executive director/VP (product lifecycle team leader, therapeutic area head) at Roche Pharmaceuticals, and senior medical director (development team leader) at Novartis and Pfizer Inc. Dr. Patni earned a BS from the City University of New York Sophie Davis School of Biomedical Education (accelerated BS/MD Program) and an MD from the Mount Sinai School of Medicine. He completed his residency and fellowship in internal medicine and cardiology at the Albert Einstein College of Medicine in New York, where he was also an attending physician.

Jennifer J. Rhodes

Chief Business Officer, General Counsel, Chief Compliance
Officer, and Corporate Secretary

Ms. Rhodes joined Adamas as general counsel and corporate secretary in April 2016, and was subsequently appointed chief compliance officer and chief business officer in August 2016 and January 2017, respectively. She previously served as general counsel at Medivation, Inc., where she was responsible for Medivation’s legal matters and also served as corporate secretary and as chief compliance officer. Before Medivation, Ms. Rhodes was an assistant general counsel at Pfizer Inc., where she supported the US primary care business and its primary care medicines development group and served as a global product lead for Pfizer Inc.’s primary care medicines. Prior to joining Pfizer, Ms. Rhodes was an associate in the regulatory law and international trade practice areas at Weil, Gotshal & Manges, LLP. She also served as a law clerk for Chief Judge Gregory A. Carman on the United States Court of International Trade. Ms. Rhodes received a JD from Wake Forest University School of Law and a BA in economics from Newcomb College of Tulane.

Christopher B. Prentiss

Chief Accounting Officer

Mr. Prentiss joined the company in April 2015 as VP, Finance
and Controller before becoming the Chief Accounting Officer of
Adamas in September 2017. Before coming to Adamas, he was most
recently VP, Finance and Controller at InterMune, Inc., a
biotechnology company, until its acquisition by Roche. Prior to
that, Mr. Prentiss was the Controller at Dynavax Technologies
Corporation, a clinical-stage biopharmaceutical company and held the
same position at MannKind Corporation, a biotechnology company, as
well as a variety of other finance roles. Prior to joining MannKind,
Mr. Prentiss was a Senior Manager at KPMG LLP in the assurance
practice. Mr. Prentiss received a Bachelor’s of Science degree in
Accounting from Loyola Marymount University, and a Masters of
Business Administration from Indiana University. Mr. Prentiss is a
CPA licensed in California.

Michael F. Bigham

Mr. Bigham currently serves as chief executive officer and chairman of the board of directors of Paratek Pharmaceuticals, Inc.
He has more than 25 years of senior leadership experience in the
biopharmaceutical industry. From 2003 to 2015, Mr. Bigham was a
partner at Abingworth LLP, an international investment group
dedicated to life sciences and healthcare. Earlier in his career, he
served as chairman and chief executive officer of Coulter
Pharmaceuticals up until the company’s acquisition by Corixa. Mr.
Bigham currently is a member of the board of directors of InMediata
and has held several directorships, including Avila Therapeutics,
Magellan Biosciences, Portola Pharmaceuticals, Supernus
Pharmaceuticals, Avedro, and Valeritas. He received his BS from the
University of Virginia and his MBA from Stanford University.

Mardi C. Dier

Ms. Dier serves as Executive Vice President and Chief
Financial Officer of Portola Pharmaceuticals since November 2013
after joining the company in August 2006. Previously, she served as
Vice President of Investor Relations at Chiron Corporation from 2003
until its acquisition by Novartis Pharmaceuticals in April 2006.
Prior to joining Chiron, she served as a Director in the West Coast
investment banking practice at Prudential Securities, where she
focused on biotechnology and other life sciences companies. Ms. Dier
was previously at KPMG Peat Marwick in the audit department. She
holds a B.S. in biology from Stanford University and an M.B.A. from
The Anderson School at the University of California, Los Angeles. In
2013, Ms. Dier was recognized as one of the most influential Bay
Area business women by the San Francisco Business Times and was a
finalist for its Bay Area CFO of the Year Award.

Martha J. Demski

Ms. Demski has more than 30 years of experience in the fields of finance and biotechnology. She is on the board of directors of Chimerix, Inc., where she chairs the audit committee and serves on the nominating and governance committee. She also chairs the audit committee and serves on the compensation committee at Neothetics, Inc. Previously, Ms. Demski served as senior vice president and chief financial officer of Ajinomoto Althea, Inc., as well as interim chief operating officer and chief financial officer of the Sidney Kimmel Cancer Center. She has also served as chief financial officer of Vical Incorporated, where she was responsible for multiple private and public financings, including the company’s initial public offering. Additionally, Ms. Demski also has more than 13 years of banking experience with Bank of America and US Trust. She holds an MBA from The University of Chicago Booth School of Business and a BA from Michigan State University. In 2014 Ms. Demski was awarded the CFO of the Year Award of Distinction by the San Diego Business Journal. In 2017 Ms. Demski was honored as the Director of the Year in Corporate Governance by the San Diego Corporate Directors Forum.

William Ericson, JD

Mr. Ericson is a managing partner of Mohr Davidow Ventures and
a managing director of Wildcat Venture Partners. He currently serves
on the board of directors of Pacific Biosciences and Rocket Fuel, as
well as the boards of a number of privately held software and
healthcare companies. Mr. Ericson received his BSFS from Georgetown
University of Foreign Service and his JD from Northwestern
University School of Law.

Ivan Lieberburg, MD, PhD

Dr. Lieberburg is currently a member of the Tavistock Group, a
private equity firm, where he concentrates on healthcare and life
sciences investment opportunities. Prior to joining Tavistock in
2009, Dr. Lieberburg was employed at Elan Corporation, plc for 22
years, where he most recently served as executive vice president in
the Corporate Office of Technology, and chief medical officer. Prior
to joining Elan (formerly Athena Neurosciences, Inc.) in 1987, Dr.
Lieberburg held faculty positions at Albert Einstein School of
Medicine and Mount Sinai School of Medicine. He holds a PhD from
Rockefeller University and an MD from the University of Miami. Dr.
Lieberburg is the author of more than 100 publications and an
inventor on 29 patents and patent applications.

John MacPhee, MPH

Mr. MacPhee serves as chief executive officer of The JED
Foundation, a nonprofit organization that exists to reduce the risks
of substance abuse, self-harm, and suicide and to help young adults
thrive. Prior to JED, he served as executive vice president of Par
Pharmaceutical and president of Par’s Strativa Pharmaceuticals
division, where he oversaw commercial operations, clinical
development, medical affairs, and business development. Previously,
he worked at Forest Laboratories, where he led the launches of
Celexa® (citalopram), Lexapro® (escitalopram), and Namenda®
(memantine HCl). Mr. MacPhee also serves as a board member for
Bottom Line, a nonprofit organization that provides guidance
counseling to disadvantaged urban youth to help them get into
college and graduate. He earned a BA from Columbia College, an MBA
from New York University, and an MPH from Columbia University.

David L. Mahoney

Mr. Mahoney is a private equity investor and currently serves
on the board of directors of Symantec Corporation, Corcept
Therapeutics, and Mercy Corps, and as a Trustee of the Schwab Mutual
Funds and SFMOMA. Previously, Mr. Mahoney acted as co-chief
executive officer of McKesson HBOC, Inc. (now McKesson Corporation)
and as chief executive officer of McKesson LLC from July 1999 to
February 2001. He joined McKesson in 1990 as Vice President for
Strategic Planning and managed the company’s relationships with the
pharmaceutical industry. Prior to joining McKesson, Mr. Mahoney was
a principal with McKinsey & Company from 1981 to 1990. Mr. Mahoney
is an honors graduate from Harvard Business School and Princeton
University.

Our Core Values

At Adamas, the principles by which we do business and interact on behalf of our patients reflect who we are, how we think, and how we engage in the important work we do. As a pillar of our company culture, we show up each day with an energy and enthusiasm indicative of the importance of our work and the decisions we make that impact others.

Passionate
about what we do and how we do it

Expect the best work of ourselves and others
respect, challenge and support

Begin with the end in mind
think right to left, plan ahead

Data-driven and rigorous
question assumptions, facts empower decisions

Adapt to opportunity
overcome obstacles, embrace change

We are in this together
shared goals, open communication, and collaboration

Our Responsibility

Adamas takes its role as a developer and manufacturer of pharmaceutical products seriously, placing patient well-being first in all we do and deliver. We demonstrate our commitment to stakeholders by practicing our core values and adhering to the highest level of integrity and quality.

Integrity

Adamas operates with an unwavering commitment to the highest ethical standards in healthcare, upholding all applicable laws, regulations, and industry codes. Our practices, policies, and procedures, including our Code of Business Conduct and Ethics, reflect our commitment and it is our expectation that every Adamas employee, consultant, vendor, supplier, and agent embody this standard of ethics.

Quality

At Adamas, we measure quality across all company activities, procedures and clinical trials through a rigorous approach to data collection and collaboration.

We ensure that all of our people follow best practices and that our medicines reflect the primary responsibility we have to protect the health and well-being of clinical trial volunteers and patients who are prescribed our medicines.

 

We encourage the reporting of any known or suspected violations of law, regulation, our policy, procedure, or standard operating procedure associated with our business activities.

If you are aware of a situation that you believe may involve such violations, please report this information to the Legal and Compliance Department or the Chief Compliance Officer at compliance@adamaspharma.com.

You can also reach the Adamas “Speak Up” Helpline at 1-844-644-4174 or online at www.adamaspharma.ethicspoint.com. Calls can be made anonymously, except as otherwise required by law.

Partner with Us

Are you curious about our approach to time dependent biology and the opportunities we are pursuing to develop differentiated medicines for chronic neurologic diseases? Please contact us. We are always interested in exploring new opportunities to enhance the value of our products, including partnerships and collaborations. To inquire, please click here to contact us.

Brand Team Leader / Sr. Director, Marketing

The Brand Team Leader / Senior Director, Marketing will be responsible for leading the ADS-5102 Brand Team, managing all aspects of marketing and launch of Adamas’ lead product, from pre-commercialization through commercialization.   Additionally, this position oversees marketing campaigns and initiatives and will collaborate with internal stakeholders to ensure that such are implemented in alignment with product goals and objectives. Additionally, this position oversees marketing campaigns and initiatives and will collaborate with internal and external stakeholders to ensure that plans are implemented in alignment with product goals and objectives. The Brand Team Leader / Senior Director, Marketing will report to the Vice President, Marketing and is based in Emeryville, CA.

Specific Responsibilities:

Qualifications:

Competencies:

To apply for this position please send your resume to hr@adamaspharma.com with the job title in the subject line. Principals only, no recruiters please.

 

Clinical Supply Manager / Sr. Clinical Supply Manager

The Clinical Supply Manager has overall responsibility for the provision of clinical material supply for clinical trials and will work closely and collaboratively with their Manufacturing, CMC and Quality and Regulatory colleagues to ensure clinical trial supplies are provided for all clinical trials. This includes ensuring clinical trial supplies are labeled, packaged and distributed according to GXP requirements and trial protocol/enrollment specifications; ensuring clinical supply planning, inventory forecasting labeling, packaging and distribution is implemented to meet company goals. The Clinical Supply Manager is responsible for scheduling, management and oversight of the clinical trial supply, inventory tracking and acting as the technical lead with the clinical trial supply vendors. Ensures that all activities and operations are in accordance with internal policies and procedures and in accordance with government regulations. This position reports to the Clinical Program Director.

Specific Responsibilities:

Qualifications:

To apply for this position please send your resume to hr@adamaspharma.com with the job title in the subject line. Principals only, no recruiters please.
 

Medical Science Liaison

The Medical Science Liaison (MSL) is responsible for conducting medical/scientific interactions and for supporting internal activities related to medical communications, medical information and clinical research.  This position reports to the Director, Medical Science Liaison and is a field based position with a corporate headquarters in Emeryville, California.

Specific Responsibilities:

Qualifications:

To apply for this position, please click here. Principals only, no recruiters please.

 

Senior Medical Science Liaison

The Senior Medical Science Liaison (Sr. MSL) is responsible for conducting medical/scientific interactions and for supporting internal activities related to medical communications, medical information and clinical research.  This position reports to the Director, Medical Science Liaison and is field based with a corporate headquarters in Emeryville, California.

Specific Responsibilities:

Qualifications:

To apply for this position, please click here. Principals only, no recruiters please.
 

Vice President, Quality Assurance

The Vice President, Quality Assurance will be responsible for leadership and strategic direction to ensure  Adamas’s corporate  Quality Assurance activities.  The successful candidate will be responsible for all aspects of quality assurance including regulatory inspections, vendor management, quality systems clinical and preclinical compliance, disposition of commercial product and clinical supplies.  The Vice President of Quality Assurance will be based in Emeryville, California and report to the Chief Business Officer, General Counsel & Chief Compliance Officer.

The primary focus of this position is to inspire, support and maintain a culture committed to quality in Adamas’ business activities.  Specifically, this position with the quality team will be focused on ensuring the continued maintenance and continuous improvement of key GxP processes, systems and documentation to ensure adherence to our global regulatory obligations with respect to research, clinical development, manufacturing and the availability of clinical and commercial supplies.

Specific Responsibilities:

Qualifications:

To apply for this position please send your resume to hr@adamaspharma.com with the job title in the subject line. Principals only, no recruiters please.